The Life Sciences Report: Is biotech going to continue its bullish trend during 2013?
Ram Selvaraju: Yes, I think so, George. The main and important consideration is the stance of the U.S. Food and Drug Administration (FDA). There has been a lot of discussion about how the FDA has been moderating its previously risk-averse stance. Moderation was clearly the case in 2012, when we had nearly 40 drugs approved—almost double the rate at which the FDA was approving drugs in lean years such as 2007 and 2008. Clearly there has been a paradigm shift. We think enthusiasm for small-cap … [visit site to read more]
- Why M&A Flurry Has Top MKM Analyst Smiling All the Way to the Bank The Life Sciences Report: Since the end of November, biotech,...
- Special Report Reveals Biotech Stock Drivers: Michael Hay The Life Sciences Report: From a share price perspective, what’s...
- Catalysts Move Drug and Medtech Stocks: Michael Hay and Jocelyn August The Life Sciences Report: Briefly, tell me what you’re doing...
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here